Alzheimer's disease and dementia are neurodegenerative conditions that gradually impair cognitive function and memory. Alzheimer's, the most common form of dementia, typically manifests through progressive memory loss, confusion, and difficulty in reasoning or problem-solving. As these diseases advance, individuals may experience changes in behavior, language difficulties, and even challenges with motor functions.
Recent research focuses on identifying biomarkers—indicators in blood, cerebrospinal fluid, or brain imaging—that could aid in early diagnosis and monitoring of Alzheimer's. These biomarkers include beta-amyloid and tau proteins, which accumulate abnormally in the brains of affected individuals. Advances in biomarker detection offer promise for earlier intervention and more precise tracking of disease progression, potentially leading to improved management strategies and therapeutic developments in the future. Understanding these biomarkers is crucial for developing effective treatments and enhancing the quality of life for those living with Alzheimer's and dementia.
Title : Make a difference
Jacqueline Tuppen, Dementia UK, United Kingdom
Title : Imaging brain clearance in Alzheimer’s disease
Jun Hua, Johns Hopkins University , United States
Title : Association between APOE allele prevalence and Alzheimer's disease risk in Southwestern Uganda
Frank Balikoowa, African Research Center for Ageing & Dementia, Uganda
Title : Healthcare professionals in Somaliland had low levels of knowledge and attitudes towards dementia care: A pilot survey
Mohamed Abdilahi Duale, Frantz Fanon University, Somalia
Title : Association between depressive symptoms and cognitive impairment severity in a real-world memory clinic cohort
Yun Ju Hsieh, Taipei City Hospital, Taiwan
Title : Neuromodulation of scalp electroacupuncture in the treatment of autism spectrum disorder
Zhenhuan Liu, Nanhai Maternity and Children Hospital Affiliated to Guangzhou University of Chinese Medicine, China